Dr. Favret is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8613 Route 29
Ste 200N
Fairfax, VA 22031Phone+1 571-350-8400Fax+1 703-280-9596
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1996 - 1999
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1993 - 1996
Lewis Katz School of Medicine at Temple UniversityClass of 1993
Certifications & Licensure
CA State Medical License 1996 - Present
VA State Medical License 1994 - 2026- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
- Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02
Publications & Presentations
PubMed
- 11 citationsHER2-Positive Advanced Breast CancerNicholas J. Robert, Anne M. Favret
Hematology/oncology Clinics of North America. 2007-04-01 - 85 citationsDose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology PracticesNeelima Denduluri, Debra A. Patt, Yunfei Wang, Menaka Bhor, Xiaoyan Li
Journal of the National Comprehensive Cancer Network. 2015-11-01 - 13 citationsMultidisciplinary Management of Locally Advanced Breast Cancer.Robert W. Carlson, Anne M. Favret
The Breast Journal. 1999-09-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
